Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial

Benzer Materyaller

• First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5 years of age
  Yazar:: Lindgren, Line M., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months
  Yazar:: Sáez-Llorens, Xavier, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age
  Yazar:: Bravo, Lulu C., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01
  Yazar:: Dietrich, Jes, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Safeguarding vaccine production and supply strategies for polio eradication endgame
  Yazar:: Bandyopadhyay, Ananda S., ve diğerleri
  Baskı/Yayın Bilgisi: (2021)